NOKOMIS, Fla.--(BUSINESS WIRE)--Rising demand for cutting-edge stem cell therapies for diabetes could blossom into a booming market for products commercialized by Rainbow Coral Corp. (OTCBB:RBCC).
A new treatment recently described in the journal BMC Medicine uses stem cells from cord blood to re-educate a diabetic's own T cells, helping to restart pancreatic function and reduce the need for insulin.
It’s a stunning breakthrough that could eventually lead to a big increase in demand for stem cells. RBCC will assist its planned target, Nano3D Biosciences (n3D), penetrate the growing research market dedicated to the development of cutting-edge cell therapies.
Nano3D is the developer of the Bio-Assembler system, which allows researchers to grow stem cells in three dimensions. The 3D cells are superior for research and treatment than the flat cells grown using conventional methods. RBCC plans to leverage its growing network within the global biotech sector to commercialize and distribute the Bio-Assembler.
For more information on Rainbow BioSciences, Rainbow Coral’s biotech division, please visit www.rainbowbiosciences.com/investors.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ: CELG), Cardinal Health, Inc. (NYSE: CAH), Abbott Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.